UBE2D3 is a positive prognostic factor and is negatively correlated with hTERT expression in esophageal cancer
Open Access
- 3 February 2015
- journal article
- Published by Spandidos Publications in Oncology Letters
- Vol. 9 (4), 1567-1574
- https://doi.org/10.3892/ol.2015.2926
Abstract
Human telomerase reverse transcriptase (hTERT) is a critical factor in unlimited cell proliferation and immortalization, with numerous studies demonstrating that high expression of hTERT is a poor prognostic factor in various types of cancer. Ubiquitin‑conjugating enzyme E2D 3 (UBE2D3) is a member of the E2 family, and participates in the ubiquitin proteasome pathway to regulate basic cellular activities, such as cell cycle control, the DNA damage response, apoptosis, and tumorigenesis. Our previous study initially determined that downregulation of UBE2D3 expression increases hTERT expression and cell proliferation, however, the association between the expression of these two proteins and their functions in cancer tissues remains unknown. Therefore, the protein expression levels of hTERT and UBE2D3 were evaluated in 150 esophageal cancer and 30 adjacent healthy tissue samples by performing immunohistochemical analysis. Concurrently, the clinicopathological data of the enrolled patients were obtained to allow correlation analysis. It was identified that the expression of hTERT in the esophageal cancer tissues was significantly higher compared with that of the adjacent tissues (P=0.015), however, the expression of UBE2D3 was significantly lower in esophageal cancer tissues than the adjacent tissues (P=0.001). Additionally, the study demonstrated that hTERT was significantly upregulated in poorly‑differentiated, advanced tumor‑node‑metastasis (TNM) stage cancer tissues (P<0.05 for all), however, UBE2D3 expression was downregulated in poorly‑differentiated, lymph node invaded cancer tissues and recurrent cases. It was also identified that traditional factors, including tumor location, T stage, lymph node status, TNM stage, and molecular factors of hTERT and UBE2D3, were significantly associated with overall survival time (P<0.05 for all). Furthermore, UBE2D3, lymph node status and tumor location were independent prognostic factors for esophageal cancer in multivariate analysis. Most notably, hTERT and UBE2D3 expression were negatively correlated with each other. In conclusion, the findings of the present study indicated that hTERT and UBE2D3 proteins appear to be involved in the development of esophageal cancer, that UBE2D3 may a positive prognostic factor for esophageal cancer, and that UBE2D3 and hTERT expression levels are inversely correlated.Keywords
This publication has 38 references indexed in Scilit:
- Inhibition of UBE2D3 Expression Attenuates Radiosensitivity of MCF-7 Human Breast Cancer Cells by Increasing hTERT Expression and ActivityPLOS ONE, 2013
- Structural Insights into the Conformation and Oligomerization of E2∼Ubiquitin ConjugatesBiochemistry, 2012
- Prognostic Significance of Telomerase Activity and Human Telomerase Reverse Transcriptase Expression in Ampullary CarcinomaAnnals of Surgical Oncology, 2012
- Long-term Outcome of 2920 Patients With Cancers of the Esophagus and Esophagogastric JunctionAnnals of Surgery, 2011
- SLUG-induced Elevation of D1 Cyclin in Breast Cancer Cells through the Inhibition of Its UbiquitinationJournal of Biological Chemistry, 2011
- Building ubiquitin chains: E2 enzymes at workNature Reviews Molecular Cell Biology, 2009
- The promise of telomere length, telomerase activity and its regulation in the translocation-dependent cancer ESFT; clinical challenges and utilityBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2009
- Immunoexpression and prognostic role of hTERT and cyclin D1 in urothelial carcinomaAPMIS, 2008
- The functional interplay between EGFR overexpression, hTERT activation, and p53 mutation in esophageal epithelial cells with activation of stromal fibroblasts induces tumor development, invasion, and differentiationGenes & Development, 2007
- ATRA: Finding targeted APL therapy targetsBlood, 2007